ReviewCancers2025
Tumour-on-Chip Models for the Study of Ovarian Cancer: Current Challenges and Future Prospects.
Review in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Models of high-grade serous carcinoma of tubo-ovarian origin.Oncology reviews · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian cancer is a highly lethal malignancy, characterised by late-stage diagnosis, marked inter- and intra-tumoural heterogeneity, and frequent development of chemoresistance. Existing preclinical models, including conventional two-dimensional cultures, three-dimensional spheroids, and organoids, only partially recapitulate the structural and functional complexity of the ovarian tumour microenvironment (TME). Tumour-on-chip (CoC) technology has emerged as a promising alternative, enabling the co-culture of tumour and stromal cells within a microengineered platform that incorporates relevant extracellular matrix components, biochemical gradients, and biomechanical cues under precisely controlled microfluidic conditions. This review provides a comprehensive overview of CoC technology relevant to ovarian cancer research, outlining fabrication strategies, device architectures, and TME-integration approaches. We systematically analyse published ovarian cancer-specific CoC models, revealing a surprisingly limited number of studies and a lack of standardisation across design parameters, materials, and outcome measures. Based on these findings, we identify critical technical and biological considerations to inform the rational design of next-generation CoC platforms, with the aim of improving their reproducibility, translational value, and potential for personalised medicine applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.